Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF1807
- Development stage
- Preclinical
- Lead developer
- ImmunoForge
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
PF1807 is a long-acting biologic therapy being developed by ImmunoForge for the treatment of sarcopenia. It is a glucagon-like peptide-1 receptor (GLP-1R) agonist that utilizes ImmunoForge's proprietary Elastin-Like Polypeptide (ELP) fusion platform technology. This platform extends the half-life of the peptide, enabling a once-monthly dosing schedule. By targeting the GLP-1 receptor, PF1807 aims to address muscle loss and functional decline associated with sarcopenia. ImmunoForge is positioning this asset as a monthly therapy to improve patient compliance and therapeutic outcomes in muscular diseases.
02
Targets
Beyond the preview
Go deeper on PF1807.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF1807.